← Back to Search

Prostaglandin Analog

TC-002 for Glaucoma (TC-002-301 Trial)

Phase 3
Waitlist Available
Research Sponsored by TearClear Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 2, 6, and 12 at 8:00 am, 10:00 am, and 4:00 pm.
Awards & highlights

TC-002-301 Trial Summary

Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic Solution, 0.005% (TC-002) compared to latanoprost Ophthalmic Solution, 0.005% (LAT) in subjects with elevated intraocular pressure at approximately 20 study sites located in the United States

Eligible Conditions
  • Glaucoma

TC-002-301 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 2, 6, and 12 at 8:00 am, 10:00 am, and 4:00 pm.
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 2, 6, and 12 at 8:00 am, 10:00 am, and 4:00 pm. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary efficacy endpoint is the difference in mean change from baseline (CFB) in IOP
Secondary outcome measures
Secondary efficacy endpoints include diurnal (average of 8:00 AM, 10:00 AM, and 4:00 PM measurements) IOP

TC-002-301 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TC-002Experimental Treatment1 Intervention
TC-002, TearClear latanoprost ophthalmic solution, 0.005%
Group II: LAT, 0.005%Active Control1 Intervention
Commercially available FDA-approved generic latanoprost ophthalmic solution, 0.005%

Find a Location

Who is running the clinical trial?

TearClear CorpLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
West Virginia
New York
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure
2021. "Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05165290.
All > Intraocular Lens
~90 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top